Skip to content
TrustList
Logos Capital logo
Venture capital firm

Logos Capital

San Francisco biotechnology investment partnership using in-house clinical trial analytics

Logos Capital cover

About Logos Capital

In San Francisco, Logos Capital invests in biotechnology companies, combining scientific and financial expertise with in-house clinical trial analytics. The firm says its mandate is to deliver strong long-term returns for investors while financing innovation that could advance the standard of care for patients.

Clinical trial underwriting and event tracking

Each investment is underwritten with an analysis of clinical trial data, and the firm tracks the events that matter to each company, such as milestones and changes in risk. Its process treats drug development as more than scientific research, weighing clinical, regulatory and commercial factors alongside the science.

From preclinical data to commercial value

The team assesses an asset from its preclinical data through to its commercial potential, in order to estimate its intrinsic value. The firm says it screens public and private companies in its sector for those that could offer clear advances on current treatment, and that it prices its positions against that assessment.

Risk management and team expertise

Risk management is built into each decision through several layers, with the aim of keeping the investment logic aligned with the interests of the people who fund the firm. The team combines chemistry, engineering, biology, data science, medical, scientific and statistical disciplines, and the firm describes its approach as rooted in technical diligence and continuous improvement.

Companies in its investment focus

The firm's website names companies it follows, and the firm says it tracks both private and public companies across the sector. They include Aligos Therapeutics, which develops treatments for liver diseases and viral infections; ALX Oncology, which develops immuno-oncology therapies that block a checkpoint used by cancer cells; Annexon Biosciences, which develops inhibitors for complement-mediated diseases; Athira Pharma, which develops regenerative therapies for neurological disease; and Avidity Biosciences, a privately held company working on antibody oligonucleotide conjugates.

TrustList summary

Logos Capital is a biotechnology-focused investment partnership based in San Francisco. It pairs scientific and financial skills with clinical trial analytics done in-house. The name comes from the Greek word for logic and discourse.

Services

  • Biotechnology investing: direct investment in public and private companies in the sector.
  • Clinical trial underwriting: analysis of trial data as part of each investment decision.
  • Event tracking and risk management: systematic follow-up of company milestones and risks.
  • Asset assessment: reviews assets from preclinical data through to commercial potential.

Who it serves

Biotechnology companies working on new therapies. Portfolio companies named on its site include Aligos Therapeutics, ALX Oncology, Annexon Biosciences, Athira Pharma and Avidity Biosciences.

Key facts

  • Based in: San Francisco, USA
  • Team backgrounds: chemistry, engineering, biology and data science, plus medical, scientific and statistical disciplines

Summary written by TrustList from the business's own published information, Nov 2026.

Categories & features

Ask TrustList to introduce you to Logos Capital

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA - Google Privacy Policy and Terms apply.

Reviews

Write the first review of Logos Capital

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about Logos Capital.

Logos Capital alternatives

Similar listings buyers compare against this one.

Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

Startup accelerator and early-stage investor running intensive batches for new technology founders

Venture capital firm partnering with founders from first idea through to public listing

Global venture capital firm and accelerator backing early-stage technology founders, formerly called 500 Startups

Decentralised bandwidth network on which developers build and users run censorship-resistant VPN applications

Venture firm backing founders using AI and automation for health and sustainability

Venture and growth investor building communications and technology companies with entrepreneurs

Direct lender and credit manager financing private-equity-backed middle market companies